Bolt Biotherapeutics, Inc.
Clinical trials sponsored by Bolt Biotherapeutics, Inc., explained in plain language.
-
Experimental cancer drug trial halted early after only 17 patients
Disease control TerminatedThis early-stage study tested a new drug called BDC-3042, alone or with another drug (cemiplimab), in 17 people with advanced cancers such as breast, kidney, ovarian, head and neck, colorectal, lung, and skin cancer. The main goal was to check safety and find the right dose. The …
Phase: PHASE1 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 08:01 UTC
-
New drug combo for HER2 cancers shows early promise but trial ends early
Disease control TerminatedThis study tested a new drug called BDC-1001, alone or with another drug (nivolumab), in people with advanced HER2-positive cancers (like breast, stomach, or colon cancer) that no longer responded to standard treatments. The goal was to check safety and see if tumors shrank. The …
Phase: PHASE1, PHASE2 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for Hard-to-Treat breast cancer? study cut short
Disease control TerminatedThis study tested a new drug called BDC-1001, given alone or with another drug (pertuzumab), in people with advanced HER2-positive breast cancer that had already been treated with several therapies, including trastuzumab deruxtecan. The goal was to see if the drug could shrink tu…
Phase: PHASE2 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC